The use and variety ofdrugs administered to children as inhaled aerosols is increasing, but little is known about how much drug reaches the lung and how it is distributed there in different age groups. In this article the reasons for measuring aerosol deposition in children are discussed and the potential methods for doing this described. Of the methods available, only the use of radiolabelled aerosols gives accurate information on total lung deposition and distribution. The The use of inhaled drug aerosols is increasing in adults and children because it allows the direct delivery of respiratory drugs to their site of action and minimises systemic adverse effects. Inhaled drugs used in children now include bronchodilators, corticosteroids, tribavirin, and an assortment of antibiotics, and the potential value of inhaled DNAse, amiloride, surfactants, and mucolytic agents is being assessed. The lung also offers a large surface area for rapid systemic absorption of a drug, which avoids presystemic metabolism in the gut and liver and is a potential, new non-invasive route for established systemic treatments such as opiates for pain control' and perhaps insulin for diabetes.23
The use of inhaled drug aerosols is increasing in adults and children because it allows the direct delivery of respiratory drugs to their site of action and minimises systemic adverse effects. Inhaled drugs used in children now include bronchodilators, corticosteroids, tribavirin, and an assortment of antibiotics, and the potential value of inhaled DNAse, amiloride, surfactants, and mucolytic agents is being assessed. The lung also offers a large surface area for rapid systemic absorption of a drug, which avoids presystemic metabolism in the gut and liver and is a potential, new non-invasive route for established systemic treatments such as opiates for pain control' and perhaps insulin for diabetes. 23 A major shortfall of the method, however, is the uncertainty about how much drug is delivered to the lung and how this is affected by the nebuliser, the method of inhalation (face mask or mouthpiece), the age and size of the child, and the particle size of the aerosol. There are no statutory regulations requiring manufacturers to test the efficiency of inhalation apparatus, and the amount of drug reaching the lungs by using different apparatus has seldom been evaluated. This is in stark contrast to the regulations concerning new formulations of established oral treatments, in which bioequivalence must be established by the manufacturers before a product licence is granted. In adults lung deposition varies distinctly with the type of inhalation apparatus, including its particle size characteristics and total aerosol output, and is affected by the mode of inhalation and the presence oflung disease. There 
Once in vitro and animal studies have shown that suitable aerosol delivery to the lower respiratory tract may be obtained it is necessary to proceed to measurements in patients. The amount of aerosol inhaled can be measured without hazard by using a fluorescent label. The label is incorporated into the nebuliser solution and while the aerosol is being inhaled by the subject the proportion lost to the atmosphere or exhaled is trapped in a filter. At In keeping with this Chua et al have reported that age had no effect on total nebulised aerosol deposition in patients with cystic fibrosis aged 5 to 15 years, but the use of a facemask was less than half as efficient as use of a mouthpiece. 29 The apparent discrepancies between these studies may be explained by differences in the age groups studied, the nebuliser equipment and drugs used, and the patients' underlying lung disease. Further studies are necessary to clarify these differences.
Conclusions
There can be no doubt that the use of radiolabelled tracers offers an accurate and convenient method of studying drug delivery. If the measurement of delivery is coupled with measurements of clinical outcome then appropriate treatment can be adopted and inappropriate treatment discarded. The risks associated with the radiation are small compared with the potential risks of using inappropriate doses of therapeutic aerosols or inadequate apparatus in children.
